A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells
about
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyAcalabrutinib (ACP-196): a selective second-generation BTK inhibitorSecond-generation inhibitors of Bruton tyrosine kinaseImmunological and Translational Aspects of NK Cell-Based Antitumor ImmunotherapiesThe development of bispecific antibodies and their applications in tumor immune escape.Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.Immunocytokines for cancer treatment: past, present and future.Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.Immunologic approaches for the treatment of multiple myeloma.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Current progress in innovative engineered antibodies.Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.Detection of a phosphorylated glycine-serine linker in an IgG-based fusion protein.Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Bispecific antibodies: design, therapy, perspectives.Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.
P2860
Q26785828-31EAFAFD-74E0-4689-A3E7-A975D564F372Q26797345-233255D2-15F9-4B63-8A3C-9881229C2E33Q28066316-2D0BA1AE-D752-4883-A7E5-202529C02D68Q28076118-3376B938-99D0-46E4-9629-071C53DD9138Q28079180-D27543D3-2EFB-4724-BC77-29A8F308EE00Q33630292-8EE871AC-34FE-428B-82AB-9157A0592B46Q33721106-32AAF64A-D895-4822-A38A-787FC87AC77DQ34517676-2CA1EA06-8492-4DE1-A8EB-791C9337C393Q34548319-C8ADB560-0E37-4B49-8328-2A3A05D66C6FQ34550963-A1F70B52-8732-4245-8560-FBCD8A82E826Q37129564-15883A82-C4B2-4B1B-BE3B-54B0CB09BCF7Q37560208-DCBFF250-B341-4A1A-885F-8B8C015EFB5EQ37661559-F094664F-F283-42B4-B175-CCC0836AD7F7Q38558611-72138BF2-134B-4484-9FED-F73054D5ADABQ38692244-3248865A-624D-466A-AF0A-B31A94209BBDQ38989496-4C39E925-3BD8-45D8-8D78-503BFA624953Q40077818-DEB6148C-DD24-432E-9773-00B7B78BD8A3Q41489391-A804EAA9-E4DA-48E8-B627-84125483A211Q42330118-043F7376-B0DB-4A76-A470-DF54187EAE6DQ42660142-B7323C30-4723-4110-A153-2A355C15D5BDQ47138591-D5C7E758-42ED-4FA1-B4B2-E1141A57C19BQ47550223-A0D53002-F12C-4FA9-9092-55DD52603E6CQ47570404-5DE7BEF0-95BB-4282-9457-847EF3C8CDF6Q49195146-9E13833B-AEDC-41D0-BBE8-0EAB1A1BB701Q49260956-D6CBF4CE-A80E-499B-97DF-964DB92DF21C
P2860
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A tetravalent bispecific TandA ...... t lysis of CD19(+) tumor cells
@en
A tetravalent bispecific TandA ...... t lysis of CD19(+) tumor cells
@nl
type
label
A tetravalent bispecific TandA ...... t lysis of CD19(+) tumor cells
@en
A tetravalent bispecific TandA ...... t lysis of CD19(+) tumor cells
@nl
prefLabel
A tetravalent bispecific TandA ...... t lysis of CD19(+) tumor cells
@en
A tetravalent bispecific TandA ...... t lysis of CD19(+) tumor cells
@nl
P2093
P2860
P1476
A tetravalent bispecific TandA ...... t lysis of CD19(+) tumor cells
@en
P2093
Carmen Herbrecht
Eugene A Zhukovsky
Fabrice Le Gall
Fionnuala McAleese
Ivica Fucek
Johannes Duell
Kristina Ellwanger
Markus Eser
Melvyn Little
P2860
P304
P356
10.1080/19420862.2015.1029216
P577
2015-01-01T00:00:00Z